Colorectal cancer (CRC) is the second leading cause of cancer-related death in the world 1 . Most CRCs are slow growing, arising from precursor lesions such as adenomatous polyps or sessile serrated lesions. This slow growth enables a window of time to screen for both early cancer and precursor lesions 2 . However, adherence to CRC screening remains low in most developed countries, ranging from 19% in Croatia and the Czech Republic to 69% in the Basque region of Spain 3,4 . There are multiple CRC screening modalities available, including stool-based tests such as faecal immunochemical testing (FIT) and multitarget stool DNA (mtsDNA) test; blood-based tests such as septin 9; and imaging-based tests such as CT colonography (CTC), colon capsule, flexible sigmoidoscopy and colonoscopy 2 . The guidelines for CRC screening differ worldwide based on population risk, resources, and patient and society values. Our Review aims to summarize evidence on each screening modality and guidelines by various regions of the world and to highlight new screening tests that have the potential to disrupt this field. Our Review does not address post-polypectomy surveillance colonoscopy.
Stool-based testsFaecal immunochemical test. Most screening programmes throughout the world rely on faecal occult blood tests 5-7 (Box 1). Faecal occult blood tests have been demonstrated to reduce CRC incidence and mortality in randomized trials enrolling between 46,000 and 152,000 individuals at average risk when used annually or biennially 8,9 . FITs are an improvement on the guaiac method of detecting haemoglobin in the stool, using antibodies specific for human haemoglobin rather than the more non-specific peroxidase reaction 10 . FIT is also a one-sample test (compared to guaiac faecal occult blood tests, which require three samples) and is easy to complete in the patient's home, leading to improved uptake compared to guaiac-based faecal occult blood tests 11 . FITs are not affected by diet or medications and, if using a quantitative test, the sensitivity and specificity can be varied by adjusting the cut-off for a positive test 12 . The FDA-approved threshold for a positive FIT is 20 μg/g (micrograms of haemoglobin per gram of stool). The threshold for a positive test can be varied to better match colonoscopy demand with available supply 7 . In a meta-analysis, the pooled sensitivity of FIT at a threshold of 20 μg/g for CRC was 0.79, with a specificity of 0.94 (ref. 13 ). In an analysis that only included studies with colonoscopy follow-up of all participants, the one-sample FIT sensitivity for CRC was 0.75 at 20 μg/g and 0.91 at 10 μg/g (ref. 14 ) and the specificity was 0.95 at 20 μg/g and 0.90 at 10 μg/g (ref. 14 ). FIT sensitivity for advanced adenomas was 0.40 at 10 μg/g and 0.25 at 20 μg/g (ref. 14 ). With the latest recommendations to lower the screening age to 45 years 9,15-17 , it is unclear if the current or different FIT threshold for positivity should be used, pointing out a need for future research.Multiple randomized trials in the U...